NYSE:HAEMedical Equipment
Is Haemonetics’ (HAE) Apheresis Reorg Quietly Redefining Its Competitive Edge in Medical Devices?
In recent days, Haemonetics Corporation saw increased attention as sector-wide interest in medical devices coincided with internal changes, including areshaped reporting segments and updated leadership compensation estimates for President and CEO Christopher A. Simon of US$12,044,701 for 2026.
Investors are weighing this mix of sector momentum, perceptions of modest undervaluation, and Haemonetics’ consolidation of its Plasma and Blood Center units into a single Apheresis segment as they...